All three major Covid-19 ‘vaccine’ manufacturers have unveiled new names for their ‘fully authorized’ jabs, even as two pharmaceutical companies await FDA approval for their products. Following the lead of Pfizer/BioNTech, which branded its ‘fully authorized’ (and oddly, unavailable) vaccine “Comirnaty,” the second and third largest manufacturers for Europe and Canada, Moderna and AstraZeneca, are also relabeling their Covid shots.
“The Pfizer-BioNTech vaccine is Comirnaty, the Moderna vaccine will be named SpikeVax, and the AstraZeneca vaccine will be named Vaxzevria,” Health Canada said in a tweet Thursday.
“These are only name changes. There are no changes to the vaccines themselves,” Health Canada added in an attempt to quell confusion. But even vaccine supporters were confused by the name changes.
The sudden announcement raised some questions among Twitter users.
“I don’t understand WHY this is being done, I fully support vaccines and wish everybody would get vaccinated…. but I assure you, whoever made the decision made a bad one. Antivaxxers are going to have a field day with this change, and that’s very sad,” one user wrote.
“Why? Why further confuse/intimidate those who are vaccine hesitant? I understand these vaccines need actual trade names but seems this should be low priority. Send vaccines where they are needed and work to curb hesitancy,” another added.
Despite Pfizer having a ‘fully authorized’ vaccine, the vaccine manufacturer admitted that it was still sending the Covid ‘vaccine’ under the label that was initially produced under Emergency Use Authorization in the United States and under Interim Order Authorization in Canada. On Thursday, Pfizer received ‘full authorization’ in Canada, as it stated in a release.
“Pfizer Canada ULC and BioNTech SE today announced that Health Canada has granted full approval (Notice of Compliance or NOC) for COMIRNATY® to prevent COVID-19 in individuals 12 years of age and older,” Pfizer said.
“The vaccine was initially authorized for use in Canada under an Interim Order Authorization on December 9, 2020 and has been referred to as the Pfizer-BioNTech COVID-19 Vaccine,” the release said. “The authorization permitted essential rollout of vaccine doses across Canada to help provide protection during the COVID-19 pandemic, based on preclinical and clinical data, including initial data from the Phase 3 clinical trial.”
“Although the vaccine’s brand name will be COMIRNATY following this approval, Canada will continue to receive vials of the vaccine labeled as Pfizer-BioNTech COVID-19 Vaccine.,” Pfizer continued. “The formulation for Pfizer-BioNTech COVID-19 Vaccine is the same formulation as COMIRNATY and they are considered interchangeable by Health Canada to provide the COVID-19 vaccination series. Given the current ongoing pandemic, a gradual transition to new labeling with the COMIRNATY brand name will occur at a later date.”
All three of the vaccine makers’ name changes have been approved for European Union distribution.
“Spikevax it is. Moderna has earned European Medicine Association approval for the brand name of its COVID-19 vaccine, even as it awaits an FDA decision,” Fierce Pharma noted.
“With last week’s official nod in the EU, Moderna’s Spikevax joins Pfizer and BioNTech’s Comirnaty and AstraZeneca’s Vaxzevria with European brand-name approvals,” the report continued. “None of the names is approved in the U.S., though, because the vaccines are still under emergency use authorization rather than bearing full FDA approval.”
“Still, it’s likely the companies are fielding the same brand names in their vaccine applications filed or soon-to-be-filed with the FDA,” the report added.
This is an excerpt from Becker News.